Alchemax Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -1.88%
- Profit Growth -118.07%
- Ebitda -102.50%
- Net Worth -249.93%
- Total Assets 247.59%
About Alchemax Pharma
Alchemax Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 June 2019 (Five years and seven months 24 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendar Singh and Pushpa Vandrasi serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24304TG2019PTC133436
-
Company No.
133436
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Jun 2019
-
Date of AGM
29 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
What products or services does Alchemax Pharma Private Limited offer?
Alchemax Pharma Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Fruit Extracts, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Mineral Supplement, Dietary Supplements, Omega 3 Capsule, Fitness Supplements, Coenzyme Q10 Tablets and Capsules, Brain & Nervous System Drugs.
Who are the key members and board of directors at Alchemax Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendar Singh
|
Director | 17-Jun-2019 | Current |
|
Pushpa Vandrasi
|
Additional Director | 24-Jun-2021 | Current |
Financial Performance of Alchemax Pharma.
Alchemax Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 1.88% decrease. The company also saw a substantial fall in profitability, with a 118.07% decrease in profit. The company's net worth observed a substantial decline by a decrease of 249.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alchemax Pharma?
In 2022, Alchemax Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alchemax Pharma?
Unlock and access historical data on people associated with Alchemax Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alchemax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alchemax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
